Published by ECHOSENS on 2024-04-19
What is MyFibroScan? The myFibroScan app is a companion app for FibroScan®, a non-invasive solution for comprehensive management of liver health. The app provides access to an Interpretation Guide and FibroScan® based scores in an easy, fast, and intuitive way. The app utilizes data from clinical studies to assist healthcare providers in interpreting FibroScan® examination results. The scores presented in the app are educational services intended for licensed healthcare professionals.
1. - Agile™3+ is an aid to identify NAFLD patients with advanced fibrosis by combining VCTE™ and routine clinical parameters to reduce the need for liver biopsy.
2. Fibroscan® provides unique and patented biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 2500 peer-reviewed publications and 60+ international guidelines.
3. Good to excellent performance in cohorts from different clinical settings (NAFLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia).
4. High clinical performances are demonstrated in large external validation cohorts from different geographical origins.
5. High clinical performances are demonstrated in large external validation cohorts from different geographical origin.
6. - Agile™4 is an aid to early identify NAFLD patients with cirrhosis by combining VCTE™ and routine clinical parameters.
7. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.
8. The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting Fibroscan® examination results.
9. Scores enhance Fibroscan® liver disease assessment with biological markers.
10. - Fast™ is an aid to identify at risk NASH patients defined as NASH + NAS≥4 + F≥2.
11. FibroScan® is the non-invasive solution for comprehensive management of liver health.
12. Liked MyFibroScan? here are 5 Medical apps like GoodRx: Prescription Saver; Teladoc | Telehealth & Therapy; Leafly: Find Weed Near You; Weedmaps: Cannabis, Weed & CBD; Baby Tracker - Newborn Log;
Or follow the guide below to use on PC:
Select Windows version:
Install MyFibroScan app on your Windows in 4 steps below:
Download a Compatible APK for PC
Download | Developer | Rating | Current version |
---|---|---|---|
Get APK for PC → | ECHOSENS | 3.50 | 2.4.0 |
For Windows 11, check if there's a native MyFibroScan Windows app here » ». If none, follow the steps below:
Minimum requirements | Recommended |
---|---|
|
|
Download on Android: Download Android
- Interpretation Guide: The app provides an Interpretation Guide that utilizes data from clinical studies to assist healthcare providers in interpreting FibroScan® examination results.
- Scores: The app provides FibroScan® based scores that enhance liver disease assessment with biological markers. The scores are presented as educational services intended for licensed healthcare professionals.
- Agile™3+: An aid to identify NAFLD patients with advanced fibrosis by combining VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins.
- Agile™4: An aid to early identify NAFLD patients with cirrhosis by combining VCTE™ and routine clinical parameters. It can help physicians manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origins.
- Fast™: An aid to identify at-risk NASH patients defined as NASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (NAFLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast™.